Highly vascularized tumors (e.g., U87MG) with higher level of αvβ3 and CD31 have better tumor response to linifanib therapy than poorly vascularized tumors (e.g., PC-3) with low levels of αvβ3 and CD31 (Fig. 10). The gene discussed is PECAM1; the disease is neoplasm.